Compare HRMY & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | AI |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2020 | 2020 |
| Metric | HRMY | AI |
|---|---|---|
| Price | $27.73 | $8.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 14 |
| Target Price | ★ $46.70 | $14.82 |
| AVG Volume (30 Days) | 1.1M | ★ 6.3M |
| Earning Date | 05-18-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | 4.27 |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | $389,056,000.00 |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | $10.62 | ★ N/A |
| Revenue Growth | 21.51 | ★ 25.27 |
| 52 Week Low | $25.52 | $7.72 |
| 52 Week High | $40.87 | $30.24 |
| Indicator | HRMY | AI |
|---|---|---|
| Relative Strength Index (RSI) | 30.66 | 38.22 |
| Support Level | $27.66 | $7.72 |
| Resistance Level | $38.91 | $9.58 |
| Average True Range (ATR) | 1.25 | 0.57 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 54.02 | 38.15 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.